Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
The SOLO1 trial was registered at ClinicalTrials.gov (NCT01844986) on April 30, 2013; the PAOLA-1 trial was registered at ClinicalTrials.gov (NCT02477644) on June 18, 2015 (retrospectively registered); Study 19 was registered at ClinicalTrials.gov (NCT00753545) on September 12, 2008 (retrospectively registered); the SOLO2 trial was registered at ClinicalTrials.gov (NCT01874353) on June 7, 2013; the OPINION trial was registered at ClinicalTrials.gov (NCT03402841) on January 3, 2018; the LIGHT trial was registered at ClinicalTrials.gov (NCT02983799) on November 4, 2016.
Authors
- Charlie Gourley (ORCID: https://orcid.org/0000-0002-2377-7221)
- Zhongwu Lai (ORCID: https://orcid.org/0000-0002-1506-8222)
- Elizabeth A. Harrington (ORCID: https://orcid.org/0000-0003-2578-8984)
- Etienne Rouleau (ORCID: https://orcid.org/0000-0002-6316-5668)
- Alexandra Léary (ORCID: https://orcid.org/0000-0002-2043-2244)
- Simon Dearden (ORCID: https://orcid.org/0000-0002-4485-9760)
- Coumaran Égile
- Fiona Simpkins (ORCID: https://orcid.org/0000-0002-0840-2368)
- Kirsten M. Timms (ORCID: https://orcid.org/0000-0003-4923-2518)
- Karen A. Cadoo (ORCID: https://orcid.org/0000-0002-8384-7148)
- Jessica Brown (ORCID: https://orcid.org/0000-0002-9278-0598)
- Carol Aghajanian (ORCID: https://orcid.org/0000-0003-0851-3225)
- Cathy E. Elks
- Ursula A. Matulonis (ORCID: https://orcid.org/0000-0002-3103-6992)
- Pierre Lao‐Sirieix
- Eric Pujade‐Lauraine
- Isabelle Laure Ray-Coquard (ORCID: https://orcid.org/0000-0003-2472-8306)
- Benoît You (ORCID: https://orcid.org/0000-0002-3177-8857)
- Alan Barnicle (ORCID: https://orcid.org/0000-0002-1475-7587)
- Jonathan A. Ledermann (ORCID: https://orcid.org/0000-0003-3799-3539)
- Darren Hodgson (ORCID: https://orcid.org/0000-0002-6631-9626)
- Andrés Poveda (ORCID: https://orcid.org/0000-0003-4250-922X)
- Stéphanie Lheureux
Institutions
- Université Claude Bernard Lyon 1 (FR)
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Institut Gustave Roussy (FR)
- Edinburgh Cancer Research (GB)
- Princess Margaret Cancer Centre (CA)
- Hospices Civils de Lyon (FR)
- Centre Léon Bérard (FR)
- AstraZeneca (Singapore) (SG)
- Hospital Quirónsalud Barcelona (ES)
- Dana-Farber Cancer Institute (US)
- Arcagy Gineco (FR)
- AstraZeneca (United States) (US)
- Myriad Genetics (US)
- University College London (GB)
- University of Pennsylvania (US)
Publication Details
- Journal
- Genome Medicine
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13073-024-01413-5
- Citations
- 11
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- AstraZeneca